Cronos Group Announces Closing of Previously Announced $17 Million Bought Deal

November 8, 2017

Cronos Group Announces Closing of Previously Announced $17 Million Bought Deal

TORONTO, ON–(CNW- November 8, 2017) – Cronos Group Inc. (TSX-V: MJN) (OTC – Nasdaq Int’l Designation: PRMCF) (“Cronos Group”) is pleased to announce that it has closed its previously announced bought deal public offering, including the full exercise of the over-allotment option. As such, a total of 5,476,190 common shares of Cronos Group (the “Shares”) were sold at a price of $3.15 per Share for aggregate gross proceeds of approximately $17.2 million (the “Offering”).

The Offering was underwritten by a syndicate led by PI Financial Corp. as sole bookrunner and which included Canaccord Genuity Corp.

Cronos Group intends to use the net proceeds of the Offering for expanding production capacity at its wholly-owned Licensed Producer Peace Naturals Project Inc., developing infrastructure for distribution, research and development initiatives, and for general working capital purposes.

The Shares were offered by way of a short form prospectus filed by Cronos Group in each of the provinces of Canada, excluding the province of Québec, pursuant to National Instrument 44-101 – Short Form Prospectus Distributions. The securities that were sold have not been, nor will they be, registered under the U.S. Securities Act, and were not offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements.

About Cronos Group
Cronos Group is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers (“LPs”) regulated within Health Canada’s Access to Cannabis for Medical Purposes Regulations and holds a portfolio of minority investments in other Licensed Producers. The Company’s flagship LPs, Peace Naturals Project Inc. (Ontario) and Original BC Ltd. (British Columbia), are collectively situated on over 125 acres of agricultural, licensed land. Cronos Group is focused on building an international iconic brand portfolio, providing patients with personalized care, and creating value for our shareholders.

Forward-looking statements
This news release may contain “forward-looking information” and “forward-looking statements” within the meaning of applicable Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management of Cronos Group, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements of Cronos Group to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements, and the forward-looking statements are not guarantees of future performance. Except as required by law, Cronos Group disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements.

CONTACT INFORMATION

The Cronos Group.
Michael Krestell
Investor & Media Relations
(416) 603-7381 EXT #236
michael@thecronosgroup.com

76 Stafford Street, Suite 302

Toronto, Ontario M6J 2S1

Info@TheCronosGroup.com
Careers@TheCronosGroup.com

(416) 504-0004